FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295900979> ?p ?o ?g. }

• W4295900979 endingPage "e2231170" @default.
• W4295900979 startingPage "e2231170" @default.
• W4295900979 abstract "ERBB2-low (ie, ERBB2 immunohistochemistry score of 1+ or 2+ in the absence of ERBB2 gene amplification) breast cancer (BC) is a new entity, with emerging dedicated treatments. Little is known about its prognosis and response to conventional therapy compared with ERBB2-zero breast tumors (ie, those with an immunohistochemistry score of 0).To compare the outcomes for patients with ERBB2-low metastatic BC (MBC) with those of patients with ERBB2-zero MBC.This cohort study was conducted from the Epidemiological Strategy and Medical Economics MBC platform and included patients with MBC treated between 2008 and 2016 in 18 French comprehensive cancer centers. The data analysis was conducted from July 16, 2020, to April 1, 2022.The main outcome was overall survival (OS), and the secondary outcome was progression-free survival under first-line treatments (PFS1).The median (range) age was 60.0 (22.0-103.0) years. Among 15 054 patients with MBC, 4671 (31%) had ERBB2-low MBC and 10 383 (69%) had ERBB2-zero MBC. The proportion of ERBB2-low cancers was higher among patients with hormone receptor-positive MBC than those with hormone receptor-negative disease (4083 patients [33.0%] vs 588 patients [21.0%]). With a median follow-up of 49.5 months (95% CI, 48.6-50.4 months), the median OS of the ERBB2-low group was 38.0 months (95% CI, 36.4-40.5 months) compared with 33.9 months (95% CI, 32.9-34.9 months) for the ERBB2-zero group (P < .001). After adjustment for age, visceral metastases, number of metastatic sites, de novo disease, period of care, and hormone receptor status, patients with ERBB2-low MBC had slightly better OS compared with patients with ERBB2-zero MBC (adjusted hazard ratio, 0.95; 95% CI, 0.91-0.99; P = .02). In contrast, PFS1 did not differ by ERBB2 status (adjusted hazard ratio, 0.99; 95% CI, 0.95-1.02; P = .45). No significant differences in OS and PFS1 were observed in multivariate analyses by hormone receptor status and types of frontline treatment.In this large cohort study, patients with ERBB2-low MBC had a slightly better OS than those with completely ERBB2-zero tumors, but identical PFS1, which could help guide treatment selection." @default.
• W4295900979 created "2022-09-16" @default.
• W4295900979 creator A5001731251 @default.
• W4295900979 creator A5002381363 @default.
• W4295900979 creator A5013759812 @default.
• W4295900979 creator A5015719789 @default.
• W4295900979 creator A5025060489 @default.
• W4295900979 creator A5032686530 @default.
• W4295900979 creator A5034058277 @default.
• W4295900979 creator A5035439475 @default.
• W4295900979 creator A5037456829 @default.
• W4295900979 creator A5041911544 @default.
• W4295900979 creator A5050926297 @default.
• W4295900979 creator A5056565799 @default.
• W4295900979 creator A5056961294 @default.
• W4295900979 creator A5061547589 @default.
• W4295900979 creator A5062193270 @default.
• W4295900979 creator A5069540694 @default.
• W4295900979 creator A5072988299 @default.
• W4295900979 creator A5079006574 @default.
• W4295900979 creator A5079969896 @default.
• W4295900979 creator A5083556697 @default.
• W4295900979 date "2022-09-15" @default.
• W4295900979 modified "2023-09-27" @default.
• W4295900979 title "Comparison of Management and Outcomes in <i>ERBB2</i>-Low vs <i>ERBB2</i>-Zero Metastatic Breast Cancer in France" @default.
• W4295900979 cites W1951105808 @default.
• W4295900979 cites W2002671375 @default.
• W4295900979 cites W2004834404 @default.
• W4295900979 cites W2113546227 @default.
• W4295900979 cites W2128458647 @default.
• W4295900979 cites W2156878255 @default.
• W4295900979 cites W2806209829 @default.
• W4295900979 cites W2953684910 @default.
• W4295900979 cites W2988134040 @default.
• W4295900979 cites W3005585857 @default.
• W4295900979 cites W3006813318 @default.
• W4295900979 cites W3018222852 @default.
• W4295900979 cites W3112421058 @default.
• W4295900979 cites W3119128530 @default.
• W4295900979 cites W3134129955 @default.
• W4295900979 cites W3166066183 @default.
• W4295900979 cites W3166815374 @default.
• W4295900979 cites W3179156059 @default.
• W4295900979 cites W3185680595 @default.
• W4295900979 cites W3195714239 @default.
• W4295900979 cites W3207557929 @default.
• W4295900979 cites W3217088298 @default.
• W4295900979 cites W3217102177 @default.
• W4295900979 cites W4200612810 @default.
• W4295900979 cites W4205795557 @default.
• W4295900979 cites W4206529592 @default.
• W4295900979 cites W4210684267 @default.
• W4295900979 cites W4211123279 @default.
• W4295900979 cites W4220765490 @default.
• W4295900979 cites W4229028760 @default.
• W4295900979 cites W4281640394 @default.
• W4295900979 doi "https://doi.org/10.1001/jamanetworkopen.2022.31170" @default.
• W4295900979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36107428" @default.
• W4295900979 hasPublicationYear "2022" @default.
• W4295900979 type Work @default.
• W4295900979 citedByCount "13" @default.
• W4295900979 countsByYear W42959009792023 @default.
• W4295900979 crossrefType "journal-article" @default.
• W4295900979 hasAuthorship W4295900979A5001731251 @default.
• W4295900979 hasAuthorship W4295900979A5002381363 @default.
• W4295900979 hasAuthorship W4295900979A5013759812 @default.
• W4295900979 hasAuthorship W4295900979A5015719789 @default.
• W4295900979 hasAuthorship W4295900979A5025060489 @default.
• W4295900979 hasAuthorship W4295900979A5032686530 @default.
• W4295900979 hasAuthorship W4295900979A5034058277 @default.
• W4295900979 hasAuthorship W4295900979A5035439475 @default.
• W4295900979 hasAuthorship W4295900979A5037456829 @default.
• W4295900979 hasAuthorship W4295900979A5041911544 @default.
• W4295900979 hasAuthorship W4295900979A5050926297 @default.
• W4295900979 hasAuthorship W4295900979A5056565799 @default.
• W4295900979 hasAuthorship W4295900979A5056961294 @default.
• W4295900979 hasAuthorship W4295900979A5061547589 @default.
• W4295900979 hasAuthorship W4295900979A5062193270 @default.
• W4295900979 hasAuthorship W4295900979A5069540694 @default.
• W4295900979 hasAuthorship W4295900979A5072988299 @default.
• W4295900979 hasAuthorship W4295900979A5079006574 @default.
• W4295900979 hasAuthorship W4295900979A5079969896 @default.
• W4295900979 hasAuthorship W4295900979A5083556697 @default.
• W4295900979 hasBestOaLocation W42959009791 @default.
• W4295900979 hasConcept C121608353 @default.
• W4295900979 hasConcept C126322002 @default.
• W4295900979 hasConcept C143998085 @default.
• W4295900979 hasConcept C2775930923 @default.
• W4295900979 hasConcept C2780739268 @default.
• W4295900979 hasConcept C3019894029 @default.
• W4295900979 hasConcept C530470458 @default.
• W4295900979 hasConcept C71924100 @default.
• W4295900979 hasConcept C72563966 @default.
• W4295900979 hasConcept C90924648 @default.
• W4295900979 hasConceptScore W4295900979C121608353 @default.
• W4295900979 hasConceptScore W4295900979C126322002 @default.
• W4295900979 hasConceptScore W4295900979C143998085 @default.
• W4295900979 hasConceptScore W4295900979C2775930923 @default.

• next